These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


702 related items for PubMed ID: 23177553

  • 1. Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday.
    McClung M, Harris ST, Miller PD, Bauer DC, Davison KS, Dian L, Hanley DA, Kendler DL, Yuen CK, Lewiecki EM.
    Am J Med; 2013 Jan; 126(1):13-20. PubMed ID: 23177553
    [Abstract] [Full Text] [Related]

  • 2. Controversies in osteoporosis management: concerns about bisphosphonates and when are "drug holidays" required?
    McClung M.
    Clin Obstet Gynecol; 2013 Dec; 56(4):743-8. PubMed ID: 24177063
    [Abstract] [Full Text] [Related]

  • 3. Bisphosphonates in the treatment of osteoporosis.
    Diab DL, Watts NB.
    Endocrinol Metab Clin North Am; 2012 Sep; 41(3):487-506. PubMed ID: 22877426
    [Abstract] [Full Text] [Related]

  • 4. Long-term use of bisphosphonates in osteoporosis.
    Watts NB, Diab DL.
    J Clin Endocrinol Metab; 2010 Apr; 95(4):1555-65. PubMed ID: 20173017
    [Abstract] [Full Text] [Related]

  • 5. Bisphosphonates for treatment of osteoporosis: expected benefits, potential harms, and drug holidays.
    Brown JP, Morin S, Leslie W, Papaioannou A, Cheung AM, Davison KS, Goltzman D, Hanley DA, Hodsman A, Josse R, Jovaisas A, Juby A, Kaiser S, Karaplis A, Kendler D, Khan A, Ngui D, Olszynski W, Ste-Marie LG, Adachi J.
    Can Fam Physician; 2014 Apr; 60(4):324-33. PubMed ID: 24733321
    [Abstract] [Full Text] [Related]

  • 6. Safety of bisphosphonates.
    Orozco C, Maalouf NM.
    Rheum Dis Clin North Am; 2012 Nov; 38(4):681-705. PubMed ID: 23137577
    [Abstract] [Full Text] [Related]

  • 7. Antiresorptive Therapies for Osteoporosis.
    Weinerman S, Usera GL.
    Oral Maxillofac Surg Clin North Am; 2015 Nov; 27(4):555-60. PubMed ID: 26412797
    [Abstract] [Full Text] [Related]

  • 8. Use of bisphosphonates in older adults: how long is long enough?
    Dunn RL, Bird ML, Conway SE, Stratton MA.
    Consult Pharm; 2013 Jan; 28(1):39-57. PubMed ID: 23315281
    [Abstract] [Full Text] [Related]

  • 9. Benefits and risks of bisphosphonate therapy for osteoporosis.
    Khosla S, Bilezikian JP, Dempster DW, Lewiecki EM, Miller PD, Neer RM, Recker RR, Shane E, Shoback D, Potts JT.
    J Clin Endocrinol Metab; 2012 Jul; 97(7):2272-82. PubMed ID: 22523337
    [Abstract] [Full Text] [Related]

  • 10. Long-term risks of bisphosphonate therapy.
    Watts NB.
    Arq Bras Endocrinol Metabol; 2014 Jul; 58(5):523-9. PubMed ID: 25166043
    [Abstract] [Full Text] [Related]

  • 11. Osteoporosis treatments and adverse events.
    Solomon DH, Rekedal L, Cadarette SM.
    Curr Opin Rheumatol; 2009 Jul; 21(4):363-8. PubMed ID: 19412101
    [Abstract] [Full Text] [Related]

  • 12. Bisphosphonate adverse effects, lessons from large databases.
    Abrahamsen B.
    Curr Opin Rheumatol; 2010 Jul; 22(4):404-9. PubMed ID: 20473174
    [Abstract] [Full Text] [Related]

  • 13. Going on a drug holiday?
    Bonnick SL.
    J Clin Densitom; 2011 Jul; 14(4):377-83. PubMed ID: 22051091
    [No Abstract] [Full Text] [Related]

  • 14. Bisphosphonate drug holiday: choosing appropriate candidates.
    Ro C, Cooper O.
    Curr Osteoporos Rep; 2013 Mar; 11(1):45-51. PubMed ID: 23296595
    [Abstract] [Full Text] [Related]

  • 15. Bisphosphonates in the treatment of osteoporosis: a review of their contribution and controversies.
    Reid IR.
    Skeletal Radiol; 2011 Sep; 40(9):1191-6. PubMed ID: 21847749
    [Abstract] [Full Text] [Related]

  • 16. Use of drug holidays in women taking bisphosphonates.
    Diab DL, Watts NB.
    Menopause; 2014 Feb; 21(2):195-7. PubMed ID: 23921518
    [Abstract] [Full Text] [Related]

  • 17. Clinical strategies to address patients' concerns in osteoporosis management with bisphosphonates.
    Cole RE.
    Postgrad Med; 2011 Mar; 123(2):131-44. PubMed ID: 21474901
    [Abstract] [Full Text] [Related]

  • 18. Bisphosphonate drug holidays--when, why and for how long?
    Anagnostis P, Stevenson JC.
    Climacteric; 2015 Mar; 18 Suppl 2():32-8. PubMed ID: 26507608
    [Abstract] [Full Text] [Related]

  • 19. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics.
    Pazianas M, Miller P, Blumentals WA, Bernal M, Kothawala P.
    Clin Ther; 2007 Aug; 29(8):1548-58. PubMed ID: 17919538
    [Abstract] [Full Text] [Related]

  • 20. Western Osteoporosis Alliance Clinical Practice Series: Evaluating the Balance of Benefits and Risks of Long-Term Osteoporosis Therapies.
    Hanley DA, McClung MR, Davison KS, Dian L, Harris ST, Miller PD, Lewiecki EM, Kendler DL, Writing Group for the Western Osteoporosis Alliance.
    Am J Med; 2017 Jul; 130(7):862.e1-862.e7. PubMed ID: 28359721
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 36.